Lets ordinary investors buy shares in a London-listed fund that holds stakes in pre-commercial lab-grown food companies.
At a glance
- Depends onMidstream position: 4 outgoing, 5 incoming connections
- ScaleMarket cap is in the bottom 5% globally
Lets ordinary investors buy shares in a London-listed fund that holds stakes in pre-commercial lab-grown food companies.
Agronomics is a London Stock Exchange-listed fund that buys equity stakes in pre-commercial cellular agriculture companies — including Memphis Meats and Perfect Day — whose products cannot be sold to anyone until regulators like the FDA or EFSA formally approve them as safe to eat. Because those approval timelines are open-ended and undefined, no portfolio company can schedule an acquisition or IPO, so the fund's capital sits locked in illiquid private stakes for an indeterminate number of years with no recurring fee income to fill the gap. The LSE listing is what makes this workable for ordinary investors: instead of granting redemption rights or holding cash reserves, the fund lets shareholders buy and sell their exposure on the public exchange, which is something private venture funds legally cannot offer retail investors. But that same listing means any prolonged regulatory delay shows up immediately as share price volatility, and if the fund's holdings were ever deemed too illiquid for a listed structure, the exchange liquidity that substitutes for redemption rights would disappear — and so would the one thing that distinguishes it from a private fund retail investors cannot access.
How does this company make money?
The fund earns money in exactly one way: when it sells a stake in a portfolio company at a higher price than it paid. That sale can happen if a large food company acquires one of the portfolio companies, if a portfolio company lists on a stock exchange, or if a growth equity investor buys the stake in a private transaction. There are no management fees, no subscription income, and no recurring payments of any kind — every pound of return depends entirely on those exit events happening and on the portfolio companies being worth more at that point than they were when the fund invested.
What makes this company hard to replace?
Shareholders in this fund benefit from board seats and established relationships with Memphis Meats, Perfect Day, and other portfolio companies that a new entrant could not walk in and replicate. The London Stock Exchange listing itself — with its regulatory framework and the retail liquidity it provides — is not something a private competitor can simply offer. And the years of hands-on technical due diligence the fund has built up on cellular agriculture biology and bioreactor processes would take any rival years to rebuild from scratch.
What limits this company?
Neither the FDA nor EFSA has set a clear timetable for approving cultured meat as a food product. Because nobody knows when approval will come, the fund cannot predict when it will be able to sell any of its positions and return money to investors. The fund keeps committing capital through multiple funding rounds with no fixed finish line.
What does this company depend on?
The fund cannot function without FDA and EFSA novel food approvals, which determine when portfolio companies can ever generate revenue. It relies on Memphis Meats, Perfect Day, and other portfolio companies successfully developing their proprietary cell lines. Specialized bioreactor equipment suppliers must deliver the manufacturing hardware those companies need to scale up. Venture capital co-investors must keep providing follow-on funding to keep the portfolio companies alive between rounds. And the London Stock Exchange listing must remain in place for retail investors to have any way in or out.
Who depends on this company?
Retail food manufacturers looking for alternative protein ingredients would lose access to scaled fermentation-derived proteins if the fund's production partnerships with portfolio companies collapse. Plant-based food brands that depend on novel protein formulations from those same companies would face delays in developing new products. Institutional investors focused on ESG strategies would lose one of the few public-market vehicles giving them exposure to cellular agriculture returns.
How does this company scale?
The frameworks the fund uses to evaluate cellular agriculture companies — assessing cell lines, fermentation processes, and scale-up potential — can be built once and applied to new deals as more companies enter the space. What cannot be scaled cheaply is the specialist knowledge required to do that assessment properly: judging proprietary biology, bioreactor engineering, and food science requires deep expertise that standard investment teams do not have and cannot easily hire or outsource.
What external forces can significantly affect this company?
The EU Novel Food Regulation requires years of safety documentation before any approval, which extends the period during which portfolio companies are burning cash without any sales. Government incentives for alternative proteins differ sharply from country to country, which affects how quickly these products can reach consumers and what an exit might be worth. Because portfolio company funding rounds are mostly in US dollars while the fund is listed in British pounds, swings in the GBP-USD exchange rate directly affect the sterling value of those holdings.
Where is this company structurally vulnerable?
If the London Stock Exchange decided the fund's holdings were too illiquid to remain listed, or if the share price drifted so far from the underlying value of the stakes that a delisting review was triggered, the public exchange mechanism would disappear. Without it, ordinary investors would have no way to exit — and the one thing that separates this fund from a private venture vehicle they cannot legally access would be gone.
Sign in to view price data.
Sign inStructural observations derived from financial data, industry benchmarks, and supply chain position.
Companies that share the same coordination system — how they create, deliver, or capture value.
Companies that share active interpretations — structural patterns currently present in both stocks.
CompanyGraph